The Thai Trade Mark Office has very precise requirements in
relation to specifications of goods/services. Applications for
registration in relation to all goods, or even to a broad category
of goods, in a particular class, will not be accepted. Applicants
must be very specific as to the goods in relation to which they
To avoid the additional costs and delays that will inevitably
result from filing an unacceptable specification of goods and
services, and to ensure that you have an accurate estimate of costs
at the outset, it is advisable to consult a local practitioner.
If the goods or services have not been specified sufficiently
precisely, the application will be rejected unless amended
– resulting in inevitable delays. By way of example, an
application for registration in relation to cosmetics in Class 3
would be rejected. The applicant would be required to specify more
precisely the type of cosmetics in relation to which registration
was being sought e.g. cosmetics for use on cheeks, cosmetics for
use around the eyes, cosmetics for use on lips, cosmetics for use
on the neck, etc.
Failure to specify good or services accurately at the outset
will make it difficult to estimate with any degree of accuracy the
likely cost of registration. Apart from the costs involved in
amending applications, the official filing and registration fees
will vary depending on the number of goods/services specified in
the application: filing fees are approximately US$27, and
registration fees approximately US$10, per item. Whereas combined
application and registration fees for application and registration
in relation of cosmetics would be US$27, the combined fees would be
US$108 if the application were amended to include cosmetics for
cheeks, cosmetics for eyes, cosmetics for lips, and cosmetics for
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
The Indian Patent Office on April 1, 2016 denied Cipla (Applicant) limited a patent for its HIV drug comprising "ritonavir" and "darunavir" involving the patent application 1399/MUMNP/2010 entitled, "Antiretroviral Combination".
The UK electorate addressed the question of withdrawal from the European Union on June 23, 2016 in a referendum that was arranged by the Parliament, by the passage of the European Union Referendum Act, 2015.
The office of the Controller General of Patents, Copyrights and Trademark on 04.04.2016 issued a public notice abandoning nearly 200000 trademark applications which were due for processing at various stages.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).